Reviewing Cassava Sciences Inc. (SAVA)’s and Catabasis Pharmaceuticals Inc. (NASDAQ:CATB)’s results

Both Cassava Sciences Inc. (NASDAQ:SAVA) and Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cassava Sciences Inc. 4 -0.31 11.72M -0.22 0.00
Catabasis Pharmaceuticals Inc. 6 0.00 11.77M -2.65 0.00

Table 1 demonstrates Cassava Sciences Inc. and Catabasis Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Cassava Sciences Inc. 277,068,557.92% -20.7% -19.7%
Catabasis Pharmaceuticals Inc. 201,196,581.20% -61.9% -55.4%

Volatility and Risk

Cassava Sciences Inc. has a beta of 1.84 and its 84.00% more volatile than Standard & Poor’s 500. Catabasis Pharmaceuticals Inc.’s 73.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.73 beta.


The Current Ratio and Quick Ratio of Cassava Sciences Inc. are 20.1 and 20.1 respectively. Its competitor Catabasis Pharmaceuticals Inc.’s Current Ratio is 7.7 and its Quick Ratio is 7.7. Cassava Sciences Inc. can pay off short and long-term obligations better than Catabasis Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for Cassava Sciences Inc. and Catabasis Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cassava Sciences Inc. 0 0 1 3.00
Catabasis Pharmaceuticals Inc. 0 0 0 0.00

$6 is Cassava Sciences Inc.’s average price target while its potential downside is -28.99%.

Institutional & Insider Ownership

The shares of both Cassava Sciences Inc. and Catabasis Pharmaceuticals Inc. are owned by institutional investors at 41.2% and 43.5% respectively. Insiders held 16.02% of Cassava Sciences Inc. shares. Insiders Comparatively, held 1.87% of Catabasis Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cassava Sciences Inc. 20.95% 35.61% 46.72% 61.26% 59.82% 110.59%
Catabasis Pharmaceuticals Inc. 2.12% 11.37% -4.15% -2.86% -2.86% 32.27%

For the past year Cassava Sciences Inc.’s stock price has bigger growth than Catabasis Pharmaceuticals Inc.


Cassava Sciences Inc. beats Catabasis Pharmaceuticals Inc. on 8 of the 11 factors.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has preclinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.